WANT A PROFILE LIKE THIS?
Create my FREE Plan Or learn about other options
Weiren Luo
PeerJ Reviewer
770 Points

Contributions by role

Reviewer 35
Editor 735

Contributions by subject area

Bioinformatics
Gastroenterology and Hepatology
Oncology
Histology
Medical Genetics
Cell Biology
Otorhinolaryngology
Microbiology
Molecular Biology
Biochemistry
Translational Medicine
Epidemiology
Nutrition
Public Health
Genetics
Pathology
Bioengineering
Biotechnology
Drugs and Devices
Respiratory Medicine

Weiren Luo

PeerJ Reviewer

Summary

Dr. Luo got Ph.D. degree in Southern Medical University, China (Advisor: Prof. Kaitai Yao, Academician of Chinese Academy of Science), and sponsored by the China Scholarship Council and Shenzhen Goverment, he had been to University of California/Lawrence Berkeley National Laboratory (Bissell MJ's lab, Academician of American Academy of Science), University of Miami and Harvard Medical School, USA as Visiting Scholar/Doctor.

He devoted himself to "New Oncology" and "New Pathology" in the post-genomic era. He advocated that cancer research and practice should be guided by innovative theories and advanced concepts. In the current research landscape, which is predominantly centered on somatic gene mutations, he advocates that "Cancer is not a genetic disease but an ecological disease", and he proposes "Cancer ecology tree" , "Nasopharyngeal carcinoma ecology" (the first systematic theory in NPC research) and "Ecological pathology"(that is " Apply the ecological (-evolutionary) principles and approaches to study the etiology, pathogenesis, pathological changes and outcomes of human diseases) (ESI Highly Cited Paper, Cover paper). As the chief translator, he spearheaded the translation of "Rethinking Cancer" (Editor: Bernhard Strauss, Marta Bertolaso, Ingemar Ernberg, Mina J.Bissell) which constructs a comprehensive theoretical framework for understanding and treating cancer. The work introduces the concepts of the cancer systems perspective and conceptual building blocks (https://reader.gmw.cn/2024-10/25/content_37636117.htm).

Prof. Luo served as Evaluation Expert of Ministry of Education Degree and Graduate Education (China), Bentham Science Publishers Ambassador, Front Med Associate editor, J Cell Mol Med Associate editor, World J Clin Oncol Editorial board, Journal of Cancer Research Updates Editorial board,and was active to review 130 journals such as Semin Cancer Biol, J Exp Clin Cancer Res, Cancer Communications, Int J Cancer, Histopathology. Additionally, Prof. Luo was invited to take part in Times Higher Education World University Rankings, and has been selected on the World's Top 2% Scientists List 2024.

Cell Biology Oncology Pathology

Work details

Director, Cancer Research Institute

The Second Affiliated hospital of Southern University of Science and Technology
Cancer Research Institute
At the beginning of COVID-19 pandemic, Prof. Luo and his team examined the world's first case of critical COVID-19 pathological biopsy of the whole lungs, and signed the pathological report including gross changes (2020-02-15~18). The digital pathology of COVID-19 was launched for reading online globally (https://qp.91360.com/topic/284.html). On Feb 27th 2020, pathological findings of critical COVID-19 including interstitial fibrosis, vascular changes, microthrombosis and hemorrhagic necrosis were firtly reported (https://www.preprints.org/manuscript/202002.0407). This study was widely reported by nearly 100 media and academic platforms (The Paper, People's Daily, China Daily, Global Times, Hong Kong Commercial Daily, Radio France Internationale, etc). Prof. Luo was invited to discuss about COVID-19 pathology with Harvard Medical School at the remote video conference. This research was rewarded as "Outstanding Paper" in 2020 Congress of Chinese Society Pathology. As the earliest reports about the pathological changes of COVID-19, it was introduced by Shenzhen Government Information Office. Our study had over 35000 views/downloads on Preprints and 341 citations (Google scholar). These findings have been included in COVID-19 treatment guidelines in China, American College of Surgeons and British Thoracic Society.

Websites

  • https://loop.frontiersin.org/people/588275/overview
  • https://www.scholarmate.com/P/WeirenLuo

PeerJ Contributions

  • Edited 7

Academic Editor on

April 10, 2024
Comparative study of nasal cavity drug delivery efficiency with different nozzles in a 3D printed model
Shengjian Fang, Xiaoqing Rui, Yu Zhang, Zhangwei Yang, Weihua Wang
https://doi.org/10.7717/peerj.17227 PubMed 38618567
January 12, 2023
Heat treatment-induced autophagy promotes breast cancer cell invasion and metastasis via TGF-β2-mediated epithelial-mesenchymal transitions
Zhennan Li, Cheng Lu, Fengliang Wang, Haowei Guo, Zhipeng Wang, Hong Yin, Jian Li
https://doi.org/10.7717/peerj.14640 PubMed 36650834
October 25, 2022
GPX2 predicts recurrence-free survival and triggers the Wnt/β-catenin/EMT pathway in prostate cancer
Ming Yang, Xudong Zhu, Yang Shen, Qi He, Yuan Qin, Yiqun Shao, Lin Yuan, Hesong Ye
https://doi.org/10.7717/peerj.14263 PubMed 36312753
July 15, 2022
Tumor budding of cervical squamous cell carcinoma: epithelial-mesenchymal transition-like cancer stem cells?
Shaoqiu Zheng, Jing Luo, Shoucheng Xie, Shanming Lu, Qinghua Liu, Huanqin Xiao, Wenjuan Luo, Yanfang Huang, Kun Liu
https://doi.org/10.7717/peerj.13745 PubMed 35860042
March 31, 2022
Dietary fatty acid patterns and risk of oesophageal squamous cell carcinoma
Chanchan Hu, Zheng Lin, Zhiqiang Liu, Xuwei Tang, Jianyu Song, Jianbo Lin, Yuanmei Chen, Zhijian Hu
https://doi.org/10.7717/peerj.13036 PubMed 35382006
March 23, 2022
ATP11A promotes EMT by regulating Numb PRRL in pancreatic cancer cells
Lin Chen, Jingtong Tang, Weiwei Sheng, Jian Sun, Yuteng Ma, Ming Dong
https://doi.org/10.7717/peerj.13172 PubMed 35345586
February 22, 2022
Butyrate promotes oral squamous cell carcinoma cells migration, invasion and epithelial-mesenchymal transition
Wenli Zang, Junchao Liu, Fengxue Geng, Dongjuan Liu, Shuwei Zhang, Yuchao Li, Yaping Pan
https://doi.org/10.7717/peerj.12991 PubMed 35223210